SARS-CoV-2 pneumonia – Page 13 – Communicable Diseases Research

Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19

COVID-19로 입원한 성인에서 중등도 용량의 코르티코스테로이드 치료

Article

Published on 2021-01-012022-09-11
Journal: Clinical microbiology and infection : the official [Category] SARS, 치료제,

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

JAK 억제는 SARS-CoV-2 간 감염성을 감소시키고 염증 반응을 조절하여 이환율 및 사망률을 감소시킵니다

Observational Study

Published on 2021-01-012022-09-11
Journal: Science Advances [Category] 신약개발, 임상, 진단, 치료제,

[키워드] 95% CI ACE2 expression adverse events Antiviral antivirals Baricitinib benefit Cell cells Cohort controlled trials Culture cytokine Cytokine storm Efficacy elderly patients greater host protein host proteins human liver increase Inflammatory response inhibited inhibitor interferon Jak janus Janus kinase kinases liver liver cells median age Microscopy moderate-severe modulate morbidity and mortality Mortality outcome parenchymal parenchymal cells Patient platelet activation Pneumonia Randomized controlled trials reduce Replication reveal RNA-Seq SARS-CoV-2 SARS-CoV-2 pneumonia the cytokine storm Viral viral entry viral load quantification
[DOI] 10.1126/sciadv.abe4724 PMC 바로가기 [Article Type] Observational Study

Development and validation of prognostic model for predicting mortality of COVID-19 patients in Wuhan, China

Article

Published on 2020-12-312022-10-29
Journal: Scientific Reports [Category] COVID-19, MERS, SARS,

[키워드] Admission advanced age affected Aspartate transaminase assist AUC Biomarkers body temperature calibrated caused Clinical outcome clinical parameter Clinical prognosis Cohort comparable conducted country COVID-19 COVID-19 patient development elevated Factor FIVE global public health Health care high risk hospital increased risk Infection Infectious diseases Intensive Mortality multicenter Multivariate analysis Neutrophil-to-lymphocyte ratio novel coronavirus 2019 pandemic Patient patients with SARS-CoV-2 Pneumonia predicted Predictive Primary outcome Probability probability of survival Prognostic factor prognostic model Protein Respiratory tract diseases retrospective risk Risk factors SARS-CoV-2 SARS-CoV-2 pneumonia second wave survival validation cohort were assessed while Wuhan, China
[DOI] 10.1038/s41598-020-78870-6 PMC 바로가기 [Article Type] Article

SARS-Cov-2 infection in transplant-related biology: Where do we stand?

이식 관련 생물학에서의 SARS-Cov-2 감염: 우리는 어디에 서 있습니까?

Review

Published on 2020-12-292022-09-11
Journal: Annals of transplantation [Category] 치료기술, 치료제,

Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia

SARS-CoV-2 폐렴 치료를 위한 토실리주맙의 자비로운 사용

Article

Published on 2020-12-152022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] MERS, SARS, 신약개발, 진단, 치료기술,

[키워드] acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adverse adverse events anti-IL-6R antigen receptor appear approved benefit C-reactive protein C-reactive protein (CRP chimeric antigen receptor clinical and laboratory parameters clinical trials compassionate use coronavirus COVID-19 CRP cytokine Cytokine storm death Decline declines dose drug Drug administration Efficacy event examined Follow-up food Food and Drug Administration hospitalized patient hospitalized patients IL-6 IL-6R Inflammation interleukin interleukin 6 Intubated laboratory parameter Laboratory parameters mechanical ventilation morbidity morbidity and mortality Mortality occurred offer outcomes oxygen Oxygen requirements oxygen saturation oxygen saturations oxygen support pathogenic Patient patients patients with SARS-CoV-2 Placebo placebo-controlled Pneumonia predominant Preliminary data profiles proof Randomized rationale reducing required respiratory respiratory distress Respiratory distress syndrome SARS-CoV-2 SARS-CoV-2 pneumonia SARS-CoV2 Serious Adverse Event Serious Adverse Events severe acute respiratory syndrome Coronavirus Significant reduction significant reductions single-center study supported T-cell temperature therapy Tocilizumab Treatment vasopressor requirement vasopressor requirements vasopressor support
[DOI] 10.1093/cid/ciaa812 PMC 바로가기 [Article Type] Article

Detection of SARS-CoV-2 pneumonia: two case reports

SARS-CoV-2 폐렴 진단: 2건의 사례 보고

Case Reports

Published on 2020-12-112022-09-10
Journal: Journal of Medical Case Reports [Category] MERS, SARS, 진단, 치료기술,

A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol

침습성 COVID-19 및 기계 환기로 치료된 급성 호흡 부전 환자에서 CONvalescent 혈장 요법의 효능을 평가하기 위한 다기관 무작위 시험: CONFIDENT 시험 프로토콜

Study Protocol

Published on 2020-12-072022-09-01
Journal: BMC Pulmonary Medicine [Category] Fulltext, MERS, 임상, 진단,

[키워드] Acute respiratory failure alleviate Analysis approach approval Belgium Blinding board center collected Consent convalescent plasma COVID-19 COVID-19 pandemic data safety monitoring board diagnosed DSMB Efficacy Endpoint Europe Evidence evidence of Evolution of SARS-CoV-2 expected expected mortality frailty funding Health care homogeneous hospital Hospitalized Hypothesis immunization include Inclusion intensive care unit Intention intention to treat Interim Interim analyses International Intervention less mechanical ventilation mechanically ventilated patients monitoring board Mortality multicenter National Neutralizing antibodies neutralizing antibody passive immunization Patient patients patients treated peer-reviewed plasma Pneumonia randomization Randomized randomized trial reached reduce mortality reduction Registered Registration registration number Respiratory failure review risk SARS-CoV-2 SARS-CoV-2 pneumonia severe respiratory failure specific neutralizing antibodies specific neutralizing antibody Standard of care Stratification Symptom the patient therapy TRAIL treated Treatment Trial trial protocol university university hospital
[DOI] 10.1186/s12890-020-01361-x PMC 바로가기 [Article Type] Study Protocol

Clinical comorbidities, characteristics, and outcomes of mechanically ventilated patients in the State of Michigan with SARS-CoV-2 pneumonia

Observational Study

Published on 2020-12-012022-10-04
Journal: Journal of clinical anesthesia [Category] 임상,

Nutritional Support and Clinical Outcome of Severe and Critical Patients With COVID-19 Pneumonia

Nutrition

Published on 2020-11-192022-10-31
Journal: Frontiers in Nutrition [Category] COVID-19,

Recent Advances in Pathophysiology, Drug Development and Future Perspectives of SARS-CoV-2

Cell and Developmental Biology

Published on 2020-11-062022-10-31
Journal: Frontiers in Cell and Developmental Biology [Category] COVID-19,

[키워드] ACE2 acute respiratory distress addition advance Affect angiotensin-converting enzyme-2 bind Clinical data clinical trial complications Computed tomography conducted convalescent coronavirus develop development Diagnosis disease Disseminated intravascular coagulation drug Drug discovery effective Epidemic Epidemiology evaluated Future health worker highly pathogenic identify IgG antibody IgM immune response include infiltration intestinal epithelial cells lymphocytic myocarditis management pandemic Pathogenesis pathophysiology Patient care patients Perspective Pneumonia public health quantitative reverse-transcription PCR recent receptor recognize researcher SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 patient SARS-CoV-2 pneumonia shown Spike protein the disease the SARS-CoV-2 Transmission Treatment upper respiratory tract Vaccine Vaccine development
[DOI] 10.3389/fcell.2020.580202 PMC 바로가기 [Article Type] Cell and Developmental Biology